Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Emulsiderm is a topical antimicrobial emollient developed and marketed by Dermal Laboratories for the treatment and prevention of dry, itchy skin conditions, particularly eczema and dermatitis. The formulation is a cutaneous emulsion containing three active ingredients: benzalkonium chloride (0.5% w/w), liquid paraffin (25% w/w), and isopropyl myristate (25% w/w). Benzalkonium chloride is a quaternary ammonium antiseptic that acts as an antimicrobial agent by disrupting bacterial cell membranes, specifically targeting *Staphylococcus aureus*, which frequently colonizes the skin of patients with eczema. The liquid paraffin and isopropyl myristate function as emollients, providing an occlusive barrier that softens the skin and prevents transepidermal water loss. Emulsiderm is suitable for all age groups and can be administered either as a bath additive or applied directly to the skin as a leave-on treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Emulsiderm.